Eplivanserin

Sanofi Aventis kwupụtara na Disemba 2009 na ọ na-ewepụ akwụkwọ ya maka nkwado nke eplivanserin site na Nchịkwa nri na ọgwụ US na Agencylọ Ọrụ Ọgwụ na Europe.

 Usoro nke ọrụ 
Eplivanserin bụ onye na-emegide serotonin receptor subtype 5-HT2A. N'adịghị ka ọgwụ ndị na-eme ka mmadụ kwụsị ịrụ ọrụ nkụzi kasị dị umeala na 5-HT2A receptors (dịka, mirtazapine, clozapine, risperidone), eplivanserin enweghị njikọ ọ bụla na dopamine, histamine na adrenergic receptors.

 Nsonaazụ ọmụmụ 
N'ime nnwale ọgwụgwọ nke Phase II nke placebo na-achịkwa na mmadụ 351, eplivanserin belatara oge ụra site na afo nwela onwa iri nkeji 39 (ma e jiri ya tụnyere nkeji 26 n'okpuru placebo).

 Nchịkọta 
Njikọ dị n'etiti 2'-Fluoroacetophenone [445-27-2] (5) & 4-hydroxybenzaldehyde [123-08-0] (6) na-enye chalcone dị n'agbata (nakwa enone), ya bụ. CID:53982926 (7). 

(2-chloroethyl) dimethylamine (CDMA) na acetone oxime na-emeghachi omume ọnụ iji nye dimethyhaminoacetoxime (DMA acetoxime), CID:16641114 (3). 

 Hụkwa 

 Pimavanserin
 Volinanserin

 Ntụaka